Search
Royalty Pharma PLC
RPRXAdd to Watchlist
58.410USD
-0.520-0.88%
Close 09-17 16:00（ET）
26.04BMarket Cap
30.41P/E TTM
Royalty Pharma PLC (RPRX) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts giving stock ratings to Royalty Pharma PLC in the past month.
Buy
3 Strong Buy
6 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
63.304USD+8.27%
RPRX Analyst Recommendation Trends
In the current month, RPRX has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. RPRX average Analyst price target in the last month is 63.304.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
3
3
3
3
6
6
6
6
6
5
4
4
1
1
1
1
1
0
1
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
10
10
10
8
8
9
RPRX Analyst Rating for Peer Comparison
Updated: Sep 17, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Pfizer Inc
PFE
5
6
19
1
1
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, RPRX EPS is projected to reach 1.143 in FY2026Q3, following reported EPS of 0.040 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
1.33
1.21
1.28
1.14
1.50
Actual
0.50
0.67
0.04
--
--
Surprise
-62.29%
-44.36%
-96.85%
--
--
FAQs
What is Royalty Pharma PLC's expected revenue for the next quarter?
Royalty Pharma PLC's expected revenue is 843.34M.
What is Royalty Pharma PLC's price target?
Analysts forecast that Royalty Pharma PLC's price target is USD 63.30, with the highest forecast at USD 70.00 and the lowest forecast at USD 46.00.
How have Royalty Pharma PLCRPRX's recent earnings per share performed?
The market expectation was USD 0.04, while Royalty Pharma PLCRPRX's earnings per share (EPS) for the previous quarter was USD 0.67. EPS for the next quarter is expected at USD 1.14.
What is the analyst rating for Royalty Pharma PLC?
Based on the ratings of Royalty Pharma PLC's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.